A glowing marker dye attached to a special marker molecule enables surgeons to visualize prostate cancer cells in real-time, allowing for more precise removal of cancerous tissues and preservation of healthy tissue. This technology has the potential to reduce the chances of cancer recurrence and minimize life-changing side effects.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
This population-based study found that higher PSA screening prevalence was associated with lower odds of advanced disease and prostate cancer-specific mortality among men with prostate cancer. Associations varied by age, race and ethnicity, and U.S. Census region.
A cost-effectiveness analysis found that first-line MRI-based screening for prostate cancer is less effective and more costly than first-line PSA testing. Despite free MRI costs, the first-line approach resulted in increased false positives and overdiagnosis without substantial reductions in mortality.
Researchers found that increased activity of the SIX2 protein contributes to increased cell plasticity and treatment resistance in prostate cancer cells. Silencing the SIX2 gene reduces malignancy and cancer spread in hormone therapy-resistant types of cancer.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
Pharmaceutical genomic testing can optimize drug dosages and minimize adverse events in treating metastatic prostate cancer. By understanding an individual's genetic variations, clinicians can tailor treatments more effectively.
Active surveillance for favorable-risk prostate cancer demonstrated to be a safe and effective management strategy, with less than 2% developing metastatic disease. The study found no significant association between delayed treatment during surveillance and worse outcomes.
A study analyzing data from the National Cancer Database found that patients receiving care at minority-serving hospitals were 17% less likely to receive definitive treatment for breast cancer and up to 31% less likely for prostate, lung, and colon cancers. Improving treatment rates could lead to additional patient outcomes.
A new alpha-ray therapeutic agent ([At-211] PSMA-5) has been developed to target prostate-specific membrane antigen (PSMA) in refractory prostate cancer patients. The therapy has shown efficacy in animal models and is now being tested in a first-in-human clinical trial.
A genomic study of over 5,000 veterans with advanced prostate cancer reveals significant differences in frequencies of alterations associated with race and ethnicity. Alterations in immunotherapy targets were more common in Black veterans, potentially leading to opportunities for precision-based therapy.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
A recent Australian study found that 20% of prostate cancer patients were over-treated, receiving surgery despite limited life expectancy. The study suggests that cancer risk stratification is a primary determinant of treatment choices, with low-risk patients more likely to have active surveillance.
Researchers found that miR-377 reduces MYC mRNA levels, leading to increased Bax and PTEN expression and decreased CDK4. This results in induced apoptosis, inhibited proliferation, and arrested cell cycle in prostate cancer cells.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
A new questionnaire assesses sexual health concerns in female partners of prostate cancer patients, highlighting challenges with communication and feelings of isolation. The study reveals high levels of distress and depression among these women.
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
A new study suggests that longer screening intervals for prostate cancer are safe and effective when the initial PSA test is conducted at a young age. The PROBASE trial found that only 0.45% of men with low-risk PSA levels developed high PSA levels, indicating an increased risk of prostate cancer. This finding supports the idea of rais...
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
A plant-based diet is associated with a 47% lower risk of prostate cancer progression in men. Eating one or two extra servings of healthy foods daily can significantly reduce the disease's worsening chances.
Researchers developed a Pix-2-Pix GAN model to correct PSMA PET/CT images, improving image quality and quantitative markers. The AI-generated images show high correlation with original images and potential for reducing CT scans without compromising image quality.
Researchers developed Tripath to analyze 3D tissue samples, predicting clinical outcomes based on 3D morphological features. This approach outperformed traditional methods, providing promising potential for guiding critical treatment decisions.
A new study found that experienced firefighters have different epigenetic modifications linked to prostate cancer risk compared to new firefighters. Chemical exposure to PFAS is associated with these changes. The research team investigated fire department data and found a link between PFAS exposure and increased prostate cancer risk.
The PSMAfore study found that 177Lu-PSMA-617 prolonged radiographic progression-free survival and improved PSA response rate compared to a change in ARPI. Treatment with 177Lu-PSMA-617 also increased objective response rate, regardless of prior treatment.
A plant-based diet after prostate cancer diagnosis was associated with lower cancer progression risk. Higher intake of plant foods was linked to reduced disease progression in men with prostate cancer.
Men with prostate cancer who listened to mindfulness audio recordings during radiation therapy experienced significant reductions in fatigue, sleep problems, anxiety, and depressive symptoms. The study found that the mindfulness intervention was more effective than listening to relaxing music during treatment.
A study of 4,253 newly diagnosed prostate cancer patients in China found that 27.0% had concurrent cardiovascular disease and 7.2% suffered from two or more conditions. The Framingham Risk Score revealed an increased risk associated with advancing age and metabolic disorders.
Researchers at the University of Notre Dame found that adding a pre-ketone supplement to an immunotherapy treatment significantly reduced prostate cancer in laboratory settings. The combination therapy made tumors sensitive to immunotherapy, leading to 23% tumor cure rates and dramatic shrinking.
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
The ECOG-ACRIN Cancer Research Group will present late-breaking findings on prostate cancer, breast cancer, and pancreas cancer at ASCO 2024. These studies include optimal chemotherapy for Black women with breast cancer and results from the first randomized national trial in older adults with pancreas cancer.
A new urine test, MyProstateScore 2.0 (MPS2), measures 18 genes associated with prostate cancer and offers higher diagnostic accuracy than existing tests. The test reduces unnecessary prostate biopsies by up to 51% in men with a history of previous negative biopsy.
Researchers have developed a new urine-based test that identifies high-grade prostate cancer by analyzing 18 genes linked to the disease. The test, called MyProstateScore2.0, was shown to be nearly 100% correct at ruling out aggressive cancers and helped avoid up to 41% of unnecessary biopsies.
A new study supports the use of neoadjuvant chemohormonal therapy for patients with locally advanced prostate cancer, showing improved biochemical progression-free survival and treatment-free survival rates. The treatment combination offers significant benefits in controlling PSA levels and potentially improving patient outcomes.
A novel SPECT/CT acquisition method utilizing lead-212 (212Pb) can accurately detect radiopharmaceutical biodistribution in a convenient manner. This technique has the potential to change practice and increase access for patients around the world by providing more precise treatment options.
A new study found that PET/MRI can accurately classify prostate cancer patients and help avoid unnecessary biopsies. The PRIMARY scoring system showed that over 80% of unnecessary biopsies could be avoided while missing only 12.5% of clinically significant prostate cancer cases.
A new three-step prostate cancer screening method can detect aggressive cancers while minimizing the detection of insignificant ones. The study found that this approach reduces unnecessary diagnoses and may lead to improved mortality rates.
Researchers at the University of Eastern Finland have identified coregulator proteins as an alternative target to prevent drug resistance in prostate cancer. By inhibiting these proteins, the growth of drug-resistant cancer cells can be inhibited, and the activity of the glucocorticoid receptor can be limited.
A culturally sensitive video addresses prostate cancer screening disparities in the Black community. The video increased knowledge and reduced uncertainty about screenings among over 600 men, leading to a 93% intent to undergo PSA screening.
A study found that proteogenomic signatures in prostate cancer tissue from patients with African and European ancestries were associated with a higher risk of metastasis and/or recurrence. The study identified mutation signatures and recurrent copy number alterations that correlated with disease progression.
A biologic drug-device combination therapy has shown promising results in treating metastatic prostate cancer, with 60% of patients experiencing an objective response. The treatment, SYNC-T, uses a cold-temperature probe to kill tumor cells and release immune-stimulating neoantigens, leading to a high response rate without severe toxic...
In a preliminary report from an ongoing clinical trial, prostate cancer screenings using PSA, Kallikrein Panel, and MRI detected higher rates of cancer compared to no screening. The study found one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected in the screened group.
A randomized clinical trial found that PSA screening compared to no routine screening resulted in a small reduction in prostate cancer deaths after 15 years. The absolute reduction in deaths was modest, but the finding suggests potential benefits of PSA screening.
The CAP trial found that PSA test screening led to a small reduction in prostate cancer deaths, but also resulted in overdiagnosis of 1 in 6 cancers. The study suggests that the benefits of screening do not outweigh the potential harms.
Integrating magnetic resonance imaging (MRI) in prostate cancer screening pathways is associated with reduced unnecessary biopsies and overdiagnosis. MRI maintains clinically significant prostate cancer detection, reducing harm from overtreatment.
A simple blood test every five years is sufficient to screen low-risk men for prostate cancer, according to new research. Researchers found that only 0.13% of men with low PSA levels developed cancer after a decade.
Global prostate cancer cases are projected to double from 1.4 million in 2020 to 2.9 million by 2040, with low- and middle-income countries seeing the highest increases. The number of annual deaths is predicted to rise by 85%, mainly in LMICs due to under-diagnosis.
A global plan to combat the projected surge in prostate cancer cases worldwide by 2040 highlights the need for increased screening among high-risk populations. The report emphasizes the importance of targeted community outreach, including mobile vans, to provide earlier diagnoses and improve treatment outcomes.
Researchers from Penn Medicine will share data on the latest advances in cancer science and medicine, including novel targets in the tumor microenvironment and the influence of the microbiome on cancer therapy. The presentation is part of the American Association for Cancer Research (AACR) Annual Meeting 2024.
Researchers found that doctors can confidently skip 50% of biopsies by combining MRI-based prostate imaging reporting and data system scores with prostate-specific antigen density testing. The study suggests that this approach can decrease patient harm and healthcare costs associated with unnecessary biopsies.
A study published in International Journal of Cancer found that men with advanced degrees and higher incomes are more likely to receive comprehensive care for prostate cancer, including MRI scans and curative treatment. This leads to lower mortality rates from the disease compared to those with lower education and income.
Patients from socially vulnerable areas show increased treatment adherence when treated at 340B-participating hospitals compared to non-participating hospitals. The study found no difference in use between 340B and non-340B hospitals but noted improved adherence among patients from disadvantaged areas.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
A new study found that the COVID-19 pandemic could have led to 20,000 prostate cancer diagnoses being missed in England. The study used data from OpenSAFELY and found a significant drop in diagnosis rates during the pandemic, with a decline of 31% in 2020 and 18% in 2021.
Researchers developed a machine-learning model to assess prostate cancer biopsy samples, overcoming limitations of traditional methods. The new model, nnU-Net, provides accurate 3D segmentation of glandular tissue structures, leading to better prognostic analyses and potential improvements in patient outcomes.
New research reveals that radioguided surgery can effectively detect and remove metastatic pelvic lymph nodes in newly diagnosed prostate cancer patients. The procedure targets the prostate-specific membrane antigen, improving nodal staging to guide treatment recommendations.
A Cancer Research UK-funded study uses AI to identify two distinct subtypes of prostate cancer, termed evotypes, which could lead to personalized treatments. The discovery has the potential to improve diagnosis and treatment outcomes, saving thousands of lives in the future.
A new study found that a widely used prostate cancer test may leave black men at increased risk of overdiagnosis due to naturally higher PSA levels. The study analyzed patient records of 730,000 men and found that black men were more likely to receive a diagnosis of prostate cancer after a raised PSA test result.